US Justice Consolidates "Blindness" Lawsuits Against Novo Nordisk and Eli Lilly
Reading Time: 3 minutes
In the USA, alongside the already huge GLP-1 litigation wave, a second collective action is emerging – this time with the serious allegation that weight loss and diabetes medications could cause vision damage up to blindness . A relevant body of the US Justice (JPML) decided on Monday, December 15, 2025 , to centralize dozens of cases and consolidate them before the Federal Court in the Eastern District of Pennsylvania . The Allegation: NAION as a Possible Cause of Vision Loss At the center of this is the rare optic nerve disorder NAION (non-arteritic...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
